H. pylori Linked to Up to 22% of Global Colorectal Cancer Cases

An international review published in eGastroenterology suggests that Helicobacter pylori, a bacterium long recognized as a definitive cause of stomach cancer, may also be linked to roughly 22% of colorectal cancer cases worldwide.

Key Clinical Takeaways:
• Global pooled estimates from 43 studies indicate that 22% of colorectal cancer cases are potentially tied to H pylori exposure, dropping to 11.9% when restricted to 14 high-quality population-based studies.
• Researchers observed an increased risk ratio of 1.59-fold for colorectal cancer among individuals with exposure, though with substantial regional heterogeneity.
• Clinical experts emphasize that these findings should not immediately alter standard colorectal cancer screening protocols or prompt universal eradication efforts without further trial data.

Global Pooled Data and Regional Variations

Led by Shailja C. Shah, an associate professor of medicine in the Division of Gastroenterology at the University of California San Diego, the research team analyzed data from meta-analyses and pooled datasets examining global and regional H pylori exposure. International estimates for colorectal cancer relied on data from the Global Cancer Observatory for 2022. While the broad analysis across 43 studies pointed toward a 22% potential link, restricting the pool to 14 high-quality cohort and population-based studies with a median follow-up of 14 years reduced the estimate to 11.9%.

The analysis revealed a 1.59-fold increased risk for colorectal cancer associated with the bacterium. This risk remained consistent across subgroups including sex, age, diagnostic method, and the presence of national screening programs. However, substantial heterogeneity emerged across study settings. Higher rates of the potential bacterial burden appeared in regions with lower overall colorectal cancer incidence but rising H pylori prevalence. The Western Pacific Region bore the highest estimated burden at 25%, with Mongolia recording the highest estimated related proportion at 36% in 2022.

Eradication Reduces Long-Term Colorectal Cancer Risk

Evidence regarding the impact of H pylori eradication on colorectal cancer risk remains sparse, appearing in only four studies. A reduced risk ratio of 0.90 materialized solely after a 10-year follow-up window. Shah and her colleagues previously examined records involving more than 800,000 US veterans over 15 years, noting an absolute risk reduction in colorectal cancer incidence between 0.23% and 0.35% following eradication.

For comparison, colonoscopy achieves an absolute risk reduction in fatal colorectal cancers of 0.15% to 0.30%, and an absolute reduction in incident cases of 0.84% to 1.22%. Shah noted that while gastric cancer trials often show risk reductions within roughly 5 years, primary-prevention benefits for slower-developing cancers demand extended observation periods. The 10-year latency aligns with the natural history of both malignancies.

Infection Links Rise in Younger Birth Cohorts

An exploratory analysis showed that the proportion of colorectal cancers potentially linked to the bacterium increased in younger birth cohorts, rising from 9.5% among those born before 1947 to roughly 15% among individuals born between 1963 and 1977. This upward shift occurs alongside a marked generational decline in overall H pylori prevalence, pointing toward a latency effect where early-life infections manifest decades later.

Researchers also identified procedural overlap as a confounding factor in real-world data. Patients evaluated for upper gastrointestinal issues often undergo upper endoscopy and colonoscopy during the same clinical encounter. Such dual evaluations can artificially inflate the apparent association between the bacterium and lower intestinal tumors.

Independent Scientific Perspectives and Future Trials

Meira Epplein, a professor of population health sciences and medicine at Duke University who co-authored an editorial on the veterans study, called the connection an exciting opportunity for cancer prevention given that the underlying infection is modifiable. She noted that suspecting the infection for standard clinical indications—such as iron-deficiency anemia—should prompt thorough testing and documented cure verification.

Duco T. Mülder of Erasmus University Medical Center similarly emphasized that evidence supporting prevention is still thin, suggesting future clinical trials for eradication incorporate colorectal outcomes alongside gastric endpoints.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: Researchers report distinct biological features in early-onset colorectal cancer · H. Pylori and Stomach Cancer: Why Shared Dining Habits Increase Risk for Asians

More on Colorectal Cancer: 2026 Global Colorectal Cancer Congress to Advance Precision Medicine and Health Equity